Correlatively, recent cancer studies have shown that treatment with anti–CTLA-4 results in a reduction of intratumoral Tregs, representing a noncanonical mechanism that may contribute to therapeutic efficacy (45, 46). The gene discussed is CTLA4; the disease is cancer.